Personnel Information

写真a

NAGAO Toshikage


Job title

Junior Associate Professor

Research Areas, Keywords

B-cell lymphoma, myeloproliferative neoplasms
To the head of this page.▲

Graduating School 【 display / non-display 】

  • Miyazaki Medical College, Faculty of Medicine, 2000.03, Graduated

To the head of this page.▲

Graduate School 【 display / non-display 】

  • Tokyo Medical and Dental University, Graduate School, Division of Medicine, Doctor's Course, 2011.03, Completed

To the head of this page.▲

Campus Career 【 display / non-display 】

  • 2011.04
    -
    2017.03
    Tokyo Medical and Dental University， (Old Organization)Medical Hospital， Hospital Departments， Department of Internal Medicine， Hematology， Assistant Professor
  • 2017.04
    -
    2019.10
    Tokyo Medical and Dental University， (Old Organization)Medical Hospital， Hospital Departments， Department of Internal Medicine， Hematology， Assistant Professor
  • 2019.11
    -
    2021.09
    Tokyo Medical and Dental University， (Old Organization)Medical Hospital， Hospital Departments， Department of Internal Medicine， Hematology， Assistant Professor
  • 2021.10
    　
    　
    Tokyo Medical and Dental University， Tokyo Medical and Dental University， Division of Clinical Medicine， Department of Internal Medicine， Hematology， Assistant Professor
  • 2021.11
    -
    2022.03
    Tokyo Medical and Dental University， Graduate School of Medical and Dental Sciences， Medical and Dental Sciences， Advanced Therapeutic Sciences， Hematology， Assistant Professor
  • 2022.04
    -
    Now
    Tokyo Medical and Dental University， Graduate School of Medical and Dental Sciences， Medical and Dental Sciences， Advanced Therapeutic Sciences， Hematology， Junior Associate Professor

▼display all

To the head of this page.▲

External Career 【 display / non-display 】

  • 2014.04
    -
    2017.03
    City of Hope National Medical Center,
To the head of this page.▲

Research Areas 【 display / non-display 】

  • Hematology and medical oncology

To the head of this page.▲

Qualification Acquired 【 display / non-display 】

  • Doctor

To the head of this page.▲
 

Published Papers & Misc 【 display / non-display 】

  1. Motomura, Y; Yoshifuji, K; Tachibana, T; Takase, H; Arai, A; Tanaka, K; Okada, K; Nogami, A; Umezawa, Y; Sakashita, C; Yamamoto, M; Mori, T; Nagao, T. Clinical factors for central nervous system progression and survival in primary vitreoretinal lymphoma BRITISH JOURNAL OF HAEMATOLOGY. 2023.12; ( PubMed, DOI )

  2. Keisuke Tanaka, Ayako Ichikawa, Natsuka Umezawa, Kouhei Yamamoto, Kota Yoshifuji, Keigo Okada, Ayako Nogami, Yoshihiro Umezawa, Toshikage Nagao, Chizuko Sakashita, Takehiko Mori, Shuji Tohda, Ryuji Koike, Shinsuke Yasuda, Masahide Yamamoto. Lymphoproliferative disorder risk after methotrexate treatment for rheumatoid arthritis. Cancer Sci. 2023.09; 114 (9): 3719-3727. ( PubMed, DOI )

  3. Nagao T, Yoshifuji K, Sadato D, Motomura Y, Saito M, Yamamoto K, Yamamoto K, Nogami A. Establishment and characterization of a new activated B-cell-like DLBCL cell line, TMD12. Experimental hematology. 2022.12; 116 37-49. ( PubMed, DOI )

  4. Takase H, Arai A, Iwasaki Y, Imai A, Nagao T, Kawagishi M, Ishida T, Mochizuki M. Challenges in the diagnosis and management of vitreoretinal lymphoma - Clinical and basic approaches. Progress in retinal and eye research. 2022.02; 90 101053. ( PubMed, DOI )

  5. Izumi Y, Kanayama M, Shen Z, Kai M, Kawamura S, Akiyama M, Yamamoto M, Nagao T, Okada K, Kawamata N, Toyota S, Ohteki T. An Antibody-Drug Conjugate That Selectively Targets Human Monocyte Progenitors for Anti-Cancer Therapy. Frontiers in immunology. 2021.02; 12 618081. ( PubMed, DOI )

  6. Maryam Aftabizadeh, Yi-Jia Li, Qianqian Zhao, Chunyan Zhang, Nigus Ambaye, Jieun Song, Toshikage Nagao, Christoph Lahtz, Marwan Fakih, David K Ann, Hua Yu, Andreas Herrmann. Potent antitumor effects of cell-penetrating peptides targeting STAT3 axis. JCI Insight. 2021.01; 6 (2): ( PubMed, DOI )

  7. Masahide Yamamoto, Keisuke Tanaka, Yoshihiro Umezawa, Toshikage Nagao, Shigeo Toyota, Osamu Miura. Soluble Interleukin-2 Receptor Level at Diagnosis Predicts Prognosis of Patients With Follicular Lymphoma Irrespective of Initial Management Strategy. Anticancer Res.. 2019.09; 39 (9): 5115-5122. ( PubMed, DOI )

  8. Herrmann A, Nagao T, Zhang C, Lahtz C, Li YJ, Yue C, Mülfarth R, Yu H. An effective cell-penetrating antibody delivery platform. JCI insight. 2019.07; 4 (14): ( PubMed, DOI )

  9. Shinya Ishida, Hiroki Akiyama, Yoshihiro Umezawa, Keigo Okada, Ayako Nogami, Gaku Oshikawa, Toshikage Nagao, Osamu Miura. Mechanisms for mTORC1 activation and synergistic induction of apoptosis by ruxolitinib and BH3 mimetics or autophagy inhibitors in JAK2-V617F-expressing leukemic cells including newly established PVTL-2. Oncotarget. 2018.06; 9 (42): 26834-26851. ( PubMed, DOI )

  10. Andreas Herrmann, Christoph Lahtz, Toshikage Nagao, Joo Y Song, Wing C Chan, Heehyoung Lee, Chanyu Yue, Thomas Look, Ronja Mülfarth, Wenzhao Li, Kurt Jenkins, John Williams, Lihua E Budde, Stephen Forman, Larry Kwak, Thomas Blankenstein, Hua Yu. CTLA4 Promotes Tyk2-STAT3-Dependent B-cell Oncogenicity. Cancer Res.. 2017.09; 77 (18): 5118-5128. ( PubMed, DOI )

  11. Tanaka K, Oshikawa G, Akiyama H, Ishida S, Nagao T, Yamamoto M, Miura O. Acute myeloid leukemia with t(3;21)(q26.2;q22) developing following low-dose methotrexate therapy for rheumatoid arthritis and expressing two AML1/MDS1/EVI1 fusion proteins: A case report. Oncology letters. 2017.07; 14 (1): 97-102. ( PubMed, DOI )

  12. Yoshihiro Umezawa, Tetsuya Kurosu, Hiroki Akiyama, Nang Wu, Ayako Nogami, Toshikage Nagao, Osamu Miusa. Down regulation of Chk1 by p53 plays a role in synergistic induction of apoptosis by chemotherapeutics and inhibitors for Jak2 or BCR/ABL in hematopoietic cells. Oncotarget. 2016.06; ( PubMed )

  13. Wakaba Yamaguchi, Naofumi Yui, Toshikage Nagao, Gaku Oshikawa, Mariko Negi, Soichiro Iimori, Tomokazu Okado, Tatemitsu Rai, Shinichi Uchida. Bence-Jones Protein λ-type Multiple Myeloma Patient Withdrawn from Maintenance Hemodialysis after Long-term Bortezomib and Dexamethasone Therapy. Intern. Med.. 2016; 55 (3): 263-268. ( PubMed, DOI )

  14. T Nagao, G Oshikawa, S Ishida, H Akiyama, Y Umezawa, A Nogami, T Kurosu, O Miura. A novel MYD88 mutation, L265RPP, in Waldenström macroglobulinemia activates the NF-κB pathway to upregulate Bcl-xL expression and enhances cell survival. Blood Cancer J. 2015.05; 5 e314. ( PubMed, DOI )

  15. Ayako Nogami, Gaku Oshikawa, Keigo Okada, Shusaku Fukutake, Yoshihiro Umezawa, Toshikage Nagao, Tetsuya Kurosu, Osamu Miura. FLT3-ITD confers resistance to the PI3K/Akt pathway inhibitors by protecting the mTOR/4EBP1/Mcl-1 pathway through STAT5 activation in acute myeloid leukemia. Oncotarget. 2015.04; 6 (11): 9189-9205. ( PubMed, DOI )

  16. Toshikage Nagao, Tetsuya Kurosu, Yoshihiro Umezawa, Ayako Nogami, Gaku Oshikawa, Shuji Tohda, Masahide Yamamoto, Osamu Miura. Proliferation and survival signaling from both Jak2-V617F and Lyn involving GSK3 and mTOR/p70S6K/4EBP1 in PVTL-1 cell line newly established from acute myeloid leukemia transformed from polycythemia vera. PLoS ONE. 2014; 9 (1): e84746. ( PubMed, DOI )

  17. Nan Wu, Tetsuya Kurosu, Gaku Oshikawa, Toshikage Nagao, Osamu Miura. PECAM-1 is involved in BCR/ABL signaling and may downregulate imatinib-induced apoptosis of Philadelphia chromosome-positive leukemia cells. Int. J. Oncol.. 2013.02; 42 (2): 419-428. ( PubMed, DOI )

  18. Tetsuya Kurosu, Toshikage Nagao, Nan Wu, Gaku Oshikawa, Osamu Miura. Inhibition of the PI3K/Akt/GSK3 pathway downstream of BCR/ABL, Jak2-V617F, or FLT3-ITD downregulates DNA damage-induced Chk1 activation as well as G2/M arrest and prominently enhances induction of apoptosis. PLoS ONE. 2013; 8 (11): e79478. ( PubMed, DOI )

  19. Gaku Oshikawa, Toshikage Nagao, Nan Wu, Tetsuya Kurosu, Osamu Miura. c-Cbl and Cbl-b ligases mediate 17-allylaminodemethoxygeldanamycin-induced degradation of autophosphorylated Flt3 kinase with internal tandem duplication through the ubiquitin proteasome pathway. J. Biol. Chem.. 2011.09; 286 (35): 30263-30273. ( PubMed, DOI )

  20. Toshikage Nagao, Gaku Oshikawa, Nan Wu, Tetsuya Kurosu, Osamu Miura. DNA damage stress and inhibition of Jak2-V617F cause its degradation and synergistically induce apoptosis through activation of GSK3β. PLoS ONE. 2011; 6 (11): e27397. ( PubMed, DOI )

  21. Takatoshi Koyama, Toshikage Nagao, Hidefumi Tsunozaki, Morio Arai, Osamu Miura. Successful management of massive intraperitoneal bleeding in a hemophilia A patient with inhibitor by surgical debridement of the incomplete hematoma and administration of recombinant factor VIII and activated factor VII. Pathophysiol. Haemost. Thromb.. 2006; 35 (5): 405-407. ( PubMed, DOI )

▼display all

To the head of this page.▲

Conference Activities & Talks 【 display / non-display 】

  1. 本村 鷹多朗, 吉藤 康太, 貞任 大地, 野上 彩子, 齊藤 真貴子, 岡田 啓五, 青山 慧, 森 毅彦, 長尾 俊景. 新規GCB-DLBCL細胞株TMD13の樹立と特性評価(Establishment and characterization of TMD13. a novel GCB-type DLBCL cell line). 日本リンパ網内系学会会誌 2023.06.01

  2. Kota Yoshifuji, Yotaro Motomura, Makiko Saito, Ayako Nogami, Genji Kawade, Shiori Watabe, Kouhei Yamamoto, Takahiko Mori, Toshikage Nagao.. TPL2, a New Prognostic Factor and a Potential Therapeutic Target in ABC-DLBCL.. 64th ASH Annual Meeting and Exposition. 2022.12.11 New Orleans

  3. 高橋 直人, 松村 到, 南 陽介, 小野 孝明, 波多 智子, 大竹 茂樹, 熱田 由子, 倉田 美穂, 藤巻 克通, 長尾 俊景, 中世古 知昭, 入山 規良, 宮本 敏浩, 麻生 範雄, 清井 仁, 宮崎 泰司. ニロチニブによる慢性期慢性骨髄性白血病の無治療寛解　JALSG N-STOP216試験(Treatment-free remission in patients with CML-CP following frontline nilotinib: JALSG N-STOP 216). 日本血液学会学術集会 2021.09.01

  4. 高橋 直人, 松村 到, 南 陽介, 小野 孝明, 波多 智子, 大竹 茂樹, 熱田 由子, 倉田 美穂, 藤巻 克通, 長尾 俊景, 中世古 知昭, 入山 規良, 宮本 敏浩, 麻生 範雄, 清井 仁, 宮崎 泰司. ニロチニブによる慢性期慢性骨髄性白血病の無治療寛解　JALSG N-STOP216試験(Treatment-free remission in patients with CML-CP following frontline nilotinib: JALSG N-STOP 216). 日本血液学会学術集会 2021.09.01

  5. Naoto Takahashi, Itaru Matsumura, Yosuke Minami, Takaaki Ono, Tomoko Hata, Shigeki Ohtake, Yoshiko Atsuta, Mio Kurata, Katsumichi Fujimaki, Toshikage Nagao, Chiaki Nakaseko, Noriyoshi Iriyama, Toshihiro Miyamoto, Norio Asou, Hitoshi Kiyoi, Yasushi Miyazaki. Treatment-Free Remission in patients with Chronic Myeloid Leukemia in Chronic Phase following frontline Nilotinib: results from JALSG N-STOP216. EHA 2021 congress virtual 2021.06.09 2021.06.09

  6. Ayako Nogami, Watanabe Daisuke, Keigo Okada, Hiroki Akiyama, Yoshihiro Umezawa, Toshikage Nagao, Shuji Tohdaand Osamu Miura. FLT3-ITD Enhances Proliferation and Survival of AML Cells through Activation of RSK1 to Upregulate the mTORC1/eIF4F Pathway Cooperatively with PIM or PI3K and to Inhibit Bad and Bim. 60th ASH Annual Meeting and Exposition 2019.12.01 FL, Orange County Convention Center

  7. Tomoko Yamashita, Hiroki Tsutsumi, Kota Yoshifuji, Tatsuya Saito, Yoshihiro Umezawa, Ayako Nogami, Ken Watanabe, Toshikage Nagao, Chizduko Sakashita, Masahide Yamamoto, Ayako Arai, Norihiko Kawamata, Osamu Miura, Tetsuya Fukuda. Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma with 11q Deletion. 第79回日本血液学会学術集会 2017.10.22

  8. Ayako Nogami, Gaku Oshikawa, Shinya Ishida, Hiroki Akiyama, Yoshihiro Umezawa, Toshikage Nagao, Tetsuya Kurosu, Osamu Miura. FLT3-ITD confers resistance to PI3K/Akt inhibitors by protecting mTOR/eIF4F/Mcl-1 pathway via STAT5. 第76回日本血液学会学術集会 2014.10.31 Osaka

▼display all

To the head of this page.▲

Others 【 display / non-display 】

  • Patent Application，2018.07

    International Application No.: PTC/US18/42177
    Title of Invention: Phosphorothioate-conjugated peptides and methods of using the same
    First Named Inventor: Andreas HERRMANN

To the head of this page.▲